“We’re looking for innovative ways to both treat and prevent obesity — including creating healthier environments and designing programs for whole families.”

David Arterburn, MD, MPH
Kaiser Permanente Washington Health Research Institute Senior Investigator
Washington Permanente Medical Group, Internal Medicine

Research overview

“Obesity is the No. 1 health problem in the United States because it negatively affects our population’s health more than any other condition,” said Kaiser Permanente Washington Health Research Institute Senior Investigator David Arterburn, MD, MPH. Kaiser Permanente Washington researchers are doing practical research to learn how doctors, patients, families, employers, and policymakers can best work together to prevent and treat obesity.

“We’re focusing on 3 ways to halt the obesity epidemic,” said Senior Investigator Dori Rosenberg, PhD, MPH. “We’re helping to change obesity-promoting environments, bringing evidence-based prevention and treatment programs into health care systems, and helping people develop lifelong healthy diet and activity habits.”

Kaiser Permanente Washington obesity research areas include:

  • Helping patients and clinicians navigate the expanding options for obesity treatment, including Wegovy and other GLP-1s (short for glucagon-like peptide-1 receptor agonists)
  • Reducing sedentary behavior and promoting physical activity and healthy diet in various age groups, populations with chronic conditions, and families
  • Encouraging shared decision-making to help patients find the best way to a healthy weight
  • Implementing health coaches and nutrition support in primary care to encourage behavior changes
  • Leveraging social networks to support lifestyle change programs
  • Understanding relationships between medications and genetic factors in developing obesity
  • Supporting health system, community, and national policies that address obesity
  • Studying relationships between obesity and depression, diabetes, and other conditions
  • Understanding the long-term benefits and risks of bariatric (weight loss) surgery

“Obesity is caused by many factors, so at Kaiser Permanente Washington, we’re working on many levels,” said Paula Lozano, MD, MPH, a senior investigator and Kaiser Permanente Washington’s senior associate medical director for research and translation. “We’re improving health care to help people who are obese now. But since obesity is a societal problem, we’re also studying how to change our homes and workplaces and neighborhoods to create more healthy environments.”

Recent publications on Obesity

Crawford CL, Hansell LD, Hsu CW, Mogk J, Paz SR, Moore DD, Macias M, Bhakta BB, Ellis D, Lopez C, Jackson T, Borruso A, Graves R, Corralejo V, Gray MF, Young DR, Drewnowski A, Lewis KH, Coleman KJ Beyond the Scale: Patient Perceptions and Experiences of Bariatric Surgery Support-A Qualitative Analysis of the BELONG II Study 2026 Aug;16(4):e70093. doi: 10.1111/cob.70093. PubMed

Haneuse S, Benz L, Smith VA, Arterburn D, Maceijewski ML Long-term cardiovascular outcomes following bariatric surgery: Reconciling seemingly conflicting evidence 2026 Jul;37(4):467-475 doi:10.1097/EDE.0000000000001952. doi: 10.1097/EDE.0000000000001952. Epub 2026-01-21. PubMed

Yang J, Gu B, Pillai H, Lii J, Cronkite D, Marsolo KA, Desai RJ Using Natural Language Processing of Clinical Notes to Supplement Structured Electronic Health Record Data for Phenotyping Smoking and Obesity in a Healthcare System 2026 Jul;35(7):e70415. doi: 10.1002/pds.70415. PubMed

Curtis LH, Arterburn D, Toh S, Guo J, Hernán MA, Iturralde E, Jastreboff A, Lewis KH, Lund JL, Maciejewski ML, McCoy RG, McTigue KM, Narain K, Wee CC, Osganian SK, Hales C Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop 2026 Jun 30 doi: 10.7326/ANNALS-26-00202. Epub 2026-06-30. PubMed

Arterburn D, Curtis LH, Toh S, Bradley MC, D'Alessio D, Duchovny N, Hines D, Narain K, Parekh A, Skinner A, Wee CC, Wong JB, Wright DR, Osganian SK, Hales C Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop 2026 Jun 30 doi: 10.7326/ANNALS-25-05468. Epub 2026-06-30. PubMed

Researchers in Obesity

David E. Arterburn, MD, MPH

Senior Investigator
David.E.Arterburn@kp.org

Curriculum vitae (CV)

Allen Cheadle, PhD

Senior Investigator, KPWHRI; Senior Research Associate, CCHE
206-287-4391
Allen.D.Cheadle@kp.org

Curriculum vitae (CV)

Andrea J. Cook, PhD

Senior Biostatistics Investigator
206-287-4257
Andrea.J.Cook@kp.org

Curriculum vitae (CV)

Maricela Cruz, PhD

Associate Biostatistics Investigator
206-287-2878
Maricela.F.Cruz@kp.org

Curriculum vitae (CV)

Nicole M. Gatto, PhD, MPH

Principal Collaborative Scientist
Nicole.M.Gatto@kp.org

Curriculum vitae (CV)

Beverly B. Green, MD, MPH

Senior Investigator
206-287-2997
Bev.B.Green@kp.org

Curriculum vitae (CV)

Mikael Anne Greenwood-Hickman, MPH

Senior Collaborative Scientist
(206) 287-2908
Mikael.Anne.Greenwood-Hickman@kp.org

Curriculum vitae (CV)

Paula Lozano, MD, MPH

Senior Investigator; Director, ACT Center
206-287-2113
Paula.Lozano@kp.org

Curriculum vitae (CV)

Dori E. Rosenberg, PhD, MPH

Senior Investigator
206-287-2532
Dori.E.Rosenberg@kp.org

Curriculum vitae (CV)

Gregory E. Simon, MD, MPH

Senior Investigator
Gregory.E.Simon@kp.org

Curriculum vitae (CV)